MENLO PARK, Calif., June 10, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announces the publication of a landmark ...
Please provide your email address to receive an email when new articles are posted on . Developed at the Mayo Clinic, the test stratifies patients with obesity into one of four phenotype groups to ...
MENLO PARK, Calif. and ST. PETERSBURG, Fla, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, ...
Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results